IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

Cited by (1,000)

Items 301–400 of 1,000

1. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities
   Matthew S. Waitkus, Christopher J. Pirozzi, Casey J. Moure, Bill H. Diplas, Landon John Hansen, Austin B. Carpenter, Rui Ryan Yang, Zhaohui Wang, Brian O. Ingram, Edward D. Karoly et al. · 2017 · Cancer Research
2. Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies
   Hanumantha Rao Madala, Surendra Reddy Punganuru, Viswanath Arutla, Subhasis Misra, Thresia Thomas, Kalkunte S. Srivenugopal · 2018 · Cancers
3. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract
   Matthias Tallegas, Elodie Miquelestorena‐Standley, Corinne Bouvier, Cécile Badoual, Arnaud François, Anne Gomez‐Brouchet, Sébastien Aubert, Christine Collin, Anne Tallet, Gonzague Du Bouexic De Pinieux · 2018 · Human Pathology
4. Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
   Avaniyapuram Kannan Murugan, Ahmad Alzahrani · 2022 · British Journal of Biomedical Science
5. Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options
   Camille Tlemsani, Fréderique Larousserie, Sixtine De Percin, Virginie Audard, Djihad Hadjadj, Jeanne Chen, David Jean Biau, Philippe Anract, Benoît Terris, François Goldwasser et al. · 2023 · International Journal of Molecular Sciences
6. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma
   Peter Birner, Stefan Pusch, Christo Christov, Stiliana Mihaylova, Kalina Toumangelova‐Uzeir, Sevdalin Natchev, SEBASTIAN FRIEDRICH SCHOPPMANN, Andrey Ivanov Tchorbanov, Berthold Streubel, Jochen Tuettenberg et al. · 2014 · Cancer
7. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
   Johnny Suijker, Hans J. Baelde, Helene Roelofs, Anne‐Marie Cleton-Jansen, Judith V.M.G. Bovée · 2015 · Oncotarget
8. Local Treatment with Adjuvant Therapy for Central Atypical Cartilaginous Tumors in the Long Bones
   Edwin F. Dierselhuis, Jasper G Gerbers, Joris J. W. Ploegmakers, Martin J. Stevens, Albert J.H. Suurmeijer, Paul C. Jutte · 2016 · Journal of Bone and Joint Surgery
9. Response to PD1 inhibition in conventional chondrosarcoma
   Michael J. Wagner, Robert W. Ricciotti, Jose Gabriel Mantilla, Elizabeth T. Loggers, Seth M. Pollack, Lee D. Cranmer · 2018 · Journal for ImmunoTherapy of Cancer
10. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone
    Naser M. Ali, Stefania Niada, Anna Teresa Brini, Mark R. Morris, Sathishkumar Kurusamy, Abdullah Alholle, David S. Huen, Cristina R. Antonescu, Franck Tirode, Vaiyapuri P. Sumathi et al. · 2018 · The Journal of Pathology
11. Sarcoma and the 100,000 Genomes Project: our experience and changes to practice
    S. Prendergast, Anna‐Christina Strobl, William C. H. Cross, Nischalan Pillay, Sandra J. Strauss, Hongtao Ye, Daniel Lindsay, Roberto Tirabosco, Jane Chalker, Shazia Mahamdallie et al. · 2020 · The Journal of Pathology Clinical Research
12. Chondrosarcoma of the spine: a narrative review
    Zach A. Pennington, Jeff Ehresman, Patricia D. Pittman, Ali Karim Ahmed, Daniel Lubelski, Edward F. McCarthy, Courtney Rory Goodwin, Daniel Michael Sciubba · 2021 · The Spine Journal
13. Action at a Distance: Allostery and the Development of Drugs to Target Cancer Cell Metabolism
    Byron DeLaBarre, Jonathan Hurov, Giovanni Cianchetta, Stuart Murray, Lenny Dang · 2014 · Chemistry & Biology
14. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data
    Gamie, Zakareya, Kapriniotis, Konstantinos, Papanikolaou, Dimitra, Haagensen, Emma, Da Conceicao Ribeiro, Ricardo, Dalgarno, Kenneth, Krippner-Heidenreich, Anja, Gerrand, Craig, Tsiridis, Eleftherios, Rankin, Kenneth Samora · 2017 · Cancer Letters
15. Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system
    Andreas A. Linninger, Grant A Hartung, Benjamin P. Liu, Snezana Mirkov, Kevin M. Tangen, Rimas Vincas Lukas, Dusten J. Unruh, Charles David James, Jann Nagina Sarkaria, Craig Horbinski · 2018 · Neuro-Oncology
16. Overview of DNA methylation in adult diffuse gliomas
    Kosuke Aoki, Atsushi Natsume · 2019 · Brain Tumor Pathology
17. A study of P release from Fe-P and Ca-P via the organic acids secreted by Aspergillus niger
    Da Tian, Liyan Wang, Jun Hu, Liangliang Zhang, Ningning Zhou, Jingjing Xia, Meiyue Xu, Yusef Kianpoor Kalkhajeh, Shimei Wang, Zhen Li et al. · 2021 · The Journal of Microbiology
18. Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions
    Antoine Gilbert, Mihaela Tudor, Juliette Montanari, Kevin Commenchail, Diana Savu, Paul Lesueur, François Chevalier · 2023 · Cancers
19. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone
    Jolieke G. van Oosterwijk, Daniëlle de Jong, Maayke A.J.H. van Ruler, Pancras C.W. Hogendoorn, PD Sander Dijkstra, Carla SP van Rijswijk, Isidro Machado, Antonio Llombart‐Bosch, Károly Szuhai, Judith V.M.G. Bovée · 2012 · BMC Cancer
20. Characteristics of gliomas in patients with somatic IDH mosaicism
    Charlotte Bonnet, Laure Thomas, Dimitri Psimaras, Franck Bielle, Élodie Vauléon, Hugues Loiseau, Stéphanie Cartalat‐Carel, David Meyronet, Caroline Dehais, Jérôme Honnorat et al. · 2016 · Acta Neuropathologica Communications
21. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma
    Elisabeth F.P. Peterse, Brendy E.W.M. van den Akker, Bertine Niessen, Jan Oosting, Johnny Suijker, Yvonne de Jong, Erik H.J. Danen, Anne‐Marie Cleton-Jansen, Judith V.M.G. Bovée · 2017 · Molecular Cancer Research
22. Metabolic Alterations in Cancer Cells and the Emerging Role of Oncometabolites as Drivers of Neoplastic Change
    Zhengqiu Zhou, Elochukwu Ibekwe, Yevgen Chornenkyy · 2018 · Antioxidants
23. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance
    David Monderer, Alexandrine Luseau, Amélie Bellec, Emmanuelle David, Stéphanie Ponsolle, Soraya Saïagh, Sylvain Bercegeay, Philippe Piloquet, Marc Guillaume Denis, Laurence Lodé et al. · 2013 · Laboratory Investigation
24. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features
    Naohiro Makise, Masaya Sekimizu, Eiichi Konishi, Toru Motoi, Takashi Kubo, Hisashi Ikoma, Shun-ichi I. WATANABE, Tomotake Okuma, Nobuyoshi Hiraoka, Masashi Fukayama et al. · 2018 · Modern Pathology
25. IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma
    Sha Song, Fan Gao, Qi Li, Qi Su, Xinyun Zhang, Xiaofeng Xue, Zhiming Wang, Chenao Qian, Zhou Jin, Bing-Zong Li et al. · 2021 · Oncogene
26. IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
    Kristian A. Choate, Evan P.S. Pratt, Matthew James Jennings, Robert J. Winn, Paul B. Mann · 2024 · Biology
27. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment
    Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Ilaria Maggio, Raffaele Lodi, Alba Ariela Brandes · 2021 · Molecular Diagnosis & Therapy
28. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
    Courtney Denton Dinardo, Andreas Hochhaus, Mark G. Frattini, Karen W L Yee, Thomas Zander, Alwin Krämer, Xueying Chen, Yan Ji, Nehal S. Parikh, Joanne Choi et al. · 2022 · Journal of Cancer Research and Clinical Oncology
29. Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development
    Priya Bisht, V. Udaya Kumar, Ruchi Pandey, V. Ravichandiran, Nitesh Kumar · 2022 · Frontiers in Pharmacology
30. Molecular Pathways: IDH2 Mutations—Co-opting Cellular Metabolism for Malignant Transformation
    Eytan M. Stein · 2015 · Clinical Cancer Research
31. 2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation
    Juan M. Schvartzman, Vincent P. Reuter, Richard P. Koche, Craig B. Thompson · 2019 · Proceedings of the National Academy of Sciences
32. Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
    Jeffrey Isaac Traylor, Mark N. Pernik, Aaron R. Plitt, Michael K. Lim, Tomás Garzón-Muvdi · 2021 · Cancers
33. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype
    Arjen H.G. Cleven, Evita C. H. Zwartkruis, Pancras C.W. Hogendoorn, Herman M. J. A. Kroon, Inge H. Briaire‐de Bruijn, Judith V.M.G. Bovée · 2015 · Histopathology
34. High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma
    Wei-Ren Liu, Meng‐Xin Tian, Lei Jin, Liu‐Xiao Yang, Zhen‐Bin Ding, Ying‐Hao Shen, Yuan‐Fei Peng, Jian Zhou, Shuang–Jian Qiu, Zhi Dai et al. · 2014 · Journal of Experimental & Clinical Cancer Research
35. Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
    Sanne Venneker, Alwine B. Kruisselbrink, Zuzanna Baranski, Ieva Palubeckaitė, Inge H. Briaire‐de Bruijn, Jan Oosting, Pim J. French, Erik H.J. Danen, Judith V.M.G. Bovée · 2020 · Cancers
36. Clinical development of IDH1 inhibitors for cancer therapy
    Mehrdad Zarei, Jonathan J. Hue, Omid Hajihassani, Hallie J. Graor, Erryk Katayama, Alexander W. Loftus, David Lawrence Bajor, Luke Daniel Rothermel, Ali Vaziri Gohar, Jordan Michael Winter · 2021 · Cancer Treatment Reviews
37. Digital PCR analysis of circulating tumor DNA: A biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection
    Gutteridge, Alice, Rathbone, Victoria M., Gibbons, Rebecca, Bi, Mark, Archard, Nicholas, Davies, Kate E. J., Brown, Jake, Plagnol, Vincent, Pillay, Nischalan, Amary, Fernanda et al. · 2017 · Cancer Medicine
38. IDH1, lipid metabolism and cancer: Shedding new light on old ideas
    Elena Bogdanovic · 2015 · Biochimica et Biophysica Acta (BBA) - General Subjects
39. Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry
    Rémi Longuespée, Annika K. Wefers, Elena De Vita, Aubry K. Miller, David Reuß, Wolfgang Wick, Christel C. Herold‐Mende, Mark Kriegsmann, Peter Schirmacher, Andreas von Deimling et al. · 2018 · Acta Neuropathologica Communications
40. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH
    Kristell Oizel, Catherine Gratas, Arulraj Nadaradjane, Lisa Oliver, François M. Vallette, Claire Pecqueur · 2015 · Cell Death and Disease
41. Advances in sarcoma gene mutations and therapeutic targets
    Peng Gao, Nicole A. Seebacher, Francis John Hornicek, Zheng Guo, Zhenfeng Duan · 2017 · Cancer Treatment Reviews
42. Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors
    Carlos E. de Andrea, Mikel San-Julián, Judith V.M.G. Bovée · 2017 · Surgical pathology clinics
43. Glioblastoma
    Elizabeth Anne Maher, Robert M. Bachoo · 2014 · Elsevier eBooks
44. Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter
    Carlos E. de Andrea, Pancras C.W. Hogendoorn · 2011 · The Journal of Pathology
45. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase–mutated intrahepatic cholangiocarcinomas
    J Delahousse, Loïc Verlingue, Sophie Broutin, Clémence Legoupil, Mehdi Touat, Ludovic S. Doucet, Samy Ammari, Ludovic Lacroix, Michel Pierre Ducreux, Jean‐Yves Scoazec et al. · 2018 · European Journal of Cancer
46. Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
    Sanne Venneker, Alwine B. Kruisselbrink, Inge H. Briaire‐de Bruijn, Yvonne de Jong, André J. van Wijnen, Erik H.J. Danen, Judith V.M.G. Bovée · 2019 · Cancers
47. Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors
    Katia Scotlandi, Claudia Maria Hattinger, Evelin Pellegrini, Marco Gambarotti, Massimo Serra · 2020 · Cells
48. Non-Conventional Treatments for Conventional Chondrosarcoma
    Varun Monga, Hariharasudan Mani, Angela C. Hirbe, Mohammed M. Milhem · 2020 · Cancers
49. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms
    Inga‐Marie Schaefer, Jason L. Hornick, Judith V.M.G. Bovée · 2018 · Laboratory Investigation
50. Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
    Michael J. Buege, Adam J. DiPippo, Courtney Denton Dinardo · 2018 · Cancers
51. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Mia Y. Platt, Amir Tahmasb Fathi, Darrell R. Borger, Andrew Mark Brunner, Robert Paul Hasserjian, Leonora Balaj, Amy M. Lum, Stephen S. F. Yip, Dora C. Dias-Santagata, Zongli Zheng et al. · 2015 · Journal of Molecular Diagnostics
52. Mutant IDH1 is required for IDH1 mutated tumor cell growth
    Genglin Jin, Christopher J. Pirozzi, Lee H. Chen, Giselle Yvette Lopez, Christopher G. Duncan, Jie Feng, Ivan Spasojević, Darell D. Bigner, Yiping He, Hai Yan · 2012 · Oncotarget
53. IDH1‐mutant cancer cells are sensitive to cisplatin and an IDH1‐mutant inhibitor counteracts this sensitivity
    Mohammed Khurshed, Niels Aarnoudse, Renske Hulsbos, Vashendriya V.V. Hira, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, Remco Jurriaan Molenaar, Cornelis J.F. Van Noorden · 2018 · The FASEB Journal
54. Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer
    Jinxiu Guo, Ruyue Zhang, Zhe Yang, Zhenfeng Duan, De-Tao Yin, Yubing Zhou · 2021 · Frontiers in Oncology
55. Unraveling the mystery of cancer metabolism in the genesis of tumor-initiating cells and development of cancer
    Gaochuan Zhang, Ping Yang, Peng-Da Guo, Lucio Miele, Fazlul H. Sarkar, Zhiwei Peter Wang, Quansheng Zhou · 2013 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
56. Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy.
    Diyang Xie, Zhenggang Ren, Jia Fan, Qiang Gao · 2016 · PubMed Central
57. Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?
    Elena Cojocaru, Christopher P. Wilding, Bodil Engelman, Paul H. Huang, Robin L. Jones · 2020 · Current Molecular Biology Reports
58. Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
    Amrita D. Sule, Jinny Van Doorn, Ranjini K. Sundaram, Sachita Ganesa, Juan C. Vasquez, Ranjit S. Bindra · 2021 · NAR Cancer
59. Role of Next-Generation Sequencing as a Diagnostic Tool for the Evaluation of Bone and Soft-Tissue Tumors
    Kinga Szurián, Karl Kashofer, Bernadette Liegl‐Atzwanger · 2017 · Pathobiology
60. The CDKN2A G500 Allele Is More Frequent in GBM Patients with No Defined Telomere Maintenance Mechanism Tumors and Is Associated with Poorer Survival
    Janice A. Royds, Shafagh Al Nadaf, Anna K. Wiles, Yu-Jen Chen, Antonio Ahn, Alisha Shaw, Sara Bowie, Frederic Lam, Bruce C. Baguley, Antony W. Braithwaite et al. · 2011 · PLoS ONE
61. Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer
    Andrea Hinsch, Meta Brolund, Claudia Hube‐Magg, Martina Kluth, Ronald Simon, Christina Möller‐Koop, Guido Sauter, Stefan A. Steurer, Andreas M. Luebke, Alexander Angerer et al. · 2018 · World Journal of Urology
62. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1 -mutant glioblastoma: a case report from a Phase I study
    Dalissa Tejera, Marina Kushnirsky, Sakir Humayun Gultekin, Min Lu, Lori Steelman, Macarena Ines de la Fuente · 2020 · CNS Oncology
63. IDH1 deficiency attenuates gluconeogenesis in mouse liver by impairing amino acid utilization
    Jing Ye, Yu Gu, Feng Zhang, Yuanlin Zhao, Yuan Yuan, Zhenyue Hao, Yi Sheng, Wanda Y. Li, Andrew C. Wakeham, Rob A. Cairns et al. · 2016 · Proceedings of the National Academy of Sciences
64. IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation
    Jiang, Bin, Zhang, Jia, Xia, Jinmei, Zhao, Wentao, Wu, Yanan, Shi, Minggang, Luo, Lianzhong, Zhou, Huamin, Chen, Ai, Ma, Huanhuan et al. · 2017 · Cell Reports
65. Deciphering the Warburg Effect: Metabolic Reprogramming, Epigenetic Remodeling, and Cell Dedifferentiation
    Albert Mao Li, Jiangbin Ye · 2023 · Annual Review of Cancer Biology
66. Bone- and Cartilage-Forming Tumors and Ewing Sarcoma: An Update with a Gnathic Emphasis
    Brian D. Stewart, John David Reith, Jacquelyn A. Knapik, Angela C. Chi · 2014 · Head and Neck Pathology
67. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions
    Vivek A. Upadhyay, Andrew Mark Brunner, Amir T. Fathi · 2017 · Pharmacology & Therapeutics
68. Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes
    Cathelijn J. F. Waaijer, Carlos E. de Andrea, Andrew Hamilton, Jolieke G. van Oosterwijk, Sally E. Stringer, Judith V.M.G. Bovée · 2012 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
69. Enchondromas in children: imaging appearance with pathological correlation
    Guillaume Bierry, Darcy A. Kerr, G. Petur Nielsen, Andrew Eric Rosenberg, Ambrose J. Huang, Martin Torriani, Miriam A. Bredella · 2012 · Skeletal Radiology
70. Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma
    Jilong Yang, Matti Annala, Ping Ji, Guowen Wang, Hong Zheng, David Codgell, Xiaoling Du, Zhiwei Fang, Baocun Sun, Matti Nykter et al. · 2014 · Journal of Hematology & Oncology
71. Radiomics, Metabolic, and Molecular MRI for Brain Tumors
    Philipp Kickingereder, Ovidiu C. Andronesi · 2018 · Seminars in Neurology
72. Molecular Pathology of Bone Tumors
    Suk Wai Lam, David G.P. van IJzendoorn, Anne‐Marie Cleton-Jansen, Károly Szuhai, Judith V.M.G. Bovée · 2018 · Journal of Molecular Diagnostics
73. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate
    Tom H. Peeters, Krissie Lenting, Vincent Breukels, Sanne A. M. van Lith, Corina N. A. M. van den Heuvel, Remco Jurriaan Molenaar, Arno van Rooij, Ron A. Wevers, Paul N. Span, Arend Heerschap et al. · 2019 · Cancer & Metabolism
74. Molecular findings in maxillofacial bone tumours and its diagnostic value
    Arjen H.G. Cleven, Willem Hans Schreuder, Eline Groen, Herman M. J. A. Kroon, Daniel Baumhoer · 2019 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
75. Recurrent driver mutations in benign tumors
    Carolina Cavaliéri Gomes · 2022 · Mutation Research/Reviews in Mutation Research
76. Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1
    Mengzhu Zheng, Weiguang Sun, Suyu Gao, Shanshan Luan, Dan Li, Renqi Chen, Qian Zhang, Lixia Chen, Jiangeng Huang, Hua Li · 2017 · Oncotarget
77. Cyclin F-Dependent Degradation of RBPJ Inhibits IDH1R132H-Mediated Tumorigenesis
    Ruhi S. Deshmukh, Shalakha Sharma, Sanjeev Das · 2018 · Cancer Research
78. Sarcoma care in the era of precision medicine
    Wallander, Karin, Öfverholm, Ingegerd, Boye, Kjetil, Tsagkozis, Panagiotis, Papakonstantinou, Andri, Lin, Yingbo, Haglund de Flon, Felix · 2023 · Journal of Internal Medicine
79. Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
    Francesca Carosi, Elisabetta Broseghini, Laura Fabbri, Giacomo Corradi, Riccardo Gili, Valentina Forte, Roberta Roncarati, Daria Maria Filippini, Manuela Ferracin · 2024 · Cancers
80. Future directions in soft tissue sarcoma treatment
    Francis Hall, Victor Manuel Villalobos, Breelyn Ann Wilky · 2019 · Current Problems in Cancer
81. Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges
    Steven Daniel Green, Heiko Koenig · 2020 · Frontiers in Genetics
82. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma
    Calixto‐Hope G. Lucas, James P. Grenert, Andrew Horvai · 2020 · Archives of Pathology & Laboratory Medicine
83. Genetic alterations in chondrosarcomas – keys to targeted therapies?
    Andre M. Samuel, José C. Costa, Dieter M. Lindskog · 2014 · Cellular Oncology
84. Common Somatic Alterations Identified in Maffucci Syndrome by Molecular Karyotyping
    Mustapha Amyere, A. Dompmartin, Vinciane Wouters, Odile Enjolras, Ilkka Kaitila, Pierre‐Louis Docquier, Catherine Godfraind, John Butler Mulliken, Laurence Myriam Boon, Miikka Vikkula · 2014 · Molecular Syndromology
85. Enigmas of IDH mutations in hematology/oncology
    Michael Heuser, Michelle Maria Araujo Cruz, Ramya Goparaju, Anuhar Chaturvedi · 2015 · Experimental Hematology
86. Chondromyxoid Fibroma Arising in Craniofacial Sites
    David M. Meredith, Christopher D.�M. Fletcher, Vickie Y. Jo · 2018 · The American Journal of Surgical Pathology
87. IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53
    Bin Jiang, Wentao Zhao, Minggang Shi, Jia Zhang, Ai Chen, Huanhuan Ma, Muhammad Suleman, Furong Lin, Lin Zhou, Jinyang Wang et al. · 2018 · Journal of Biological Chemistry
88. High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study
    Chao Bi, Mei Liu, Weiqi Rong, Fan Wu, Yang Zhang, Shengtao Lin, Yunhe Liu, Jianxiong Wu, Liming Wang · 2019 · BMC Cancer
89. Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants
    Snjezana Doğan, Denise Frosina, Jerica A. Geronimo, Enmily Hernandez, Abhinita S. Mohanty, Tejus Bale, Jaclyn Frances Hechtman, Maria E. Arcila, Meera Hameed, Achim A. Jungbluth · 2020 · Human Pathology
90. Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing
    Aurélie Dupuy, François Lemonnier, Virginie Fataccioli, Nadine Martin‐Garcia, Cyrielle Robe, Romain Pelletier, Elsa Poullot, Anissa Moktefi, Karima Mokhtari, Marie Christine Rousselet et al. · 2018 · Journal of Molecular Diagnostics
91. Chondro-Osseous Lesions of Soft Tissue
    Soo‐Jin Cho, Andrew Horvai · 2015 · Surgical pathology clinics
92. IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells
    Hironori Matsunaga, Akiko Futakuchi-Tsuchida, Makoto Takahashi, TOMIO ISHIKAWA, Makoto Tsuji, Osamu Ando · 2012 · Biochemical and Biophysical Research Communications
93. Prognostic impact of the isocitrate dehydrogenase 1 single‐nucleotide polymorphism rs11554137 in malignant gliomas
    Xiao‐Wei Wang, Blandine Boisselier, Marta Rossetto, Yannick Marie, Ahmed Idbaïh, Karima Mokhtari, Konstantinos Gousias, Khê Hoang‐Xuan, Jean‐Yves Delattre, Matthias Simon et al. · 2012 · Cancer
94. Sirtuin activation targets IDH-mutant tumors
    Julie J. Miller, Alexandria L. Fink, Jack A Banagis, Hiroaki Nagashima, Megha P. Subramanian, Christine Kyuyoung Lee, Lisa Melamed, Shilpa S. Tummala, Kensuke Tateishi, Hiroaki Wakimoto et al. · 2020 · Neuro-Oncology
95. A genetic model for central chondrosarcoma evolution correlates with patient outcome
    William C. H. Cross, Iben Lyskjær, Tom Lesluyes, Steven Hargreaves, Anna‐Christina Strobl, Christopher Davies, Sara Waise, Shadi Hames-Fathi, Dahmane Oukrif, Hongtao Ye et al. · 2022 · Genome Medicine
96. Molecular diagnosis of intrahepatic cholangiocarcinoma
    Hiroaki Haga, Tushar C. Patel · 2014 · Journal of Hepato-Biliary-Pancreatic Sciences
97. Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1
    Jason M. Law, Sebastian Stark, Ke Liu, Norah E. Liang, Mahmud M. Hussain, Matthias Leiendecker, Daisuke Ito, Oscar Verho, Andrew M. Stern, Stephen E. Johnston et al. · 2016 · ACS Medicinal Chemistry Letters
98. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations
    Mika Kato Kaneko, Shunpei Morita, Yuta Tsujimoto, Ryo Yanagiya, Kana Nasu, Hiroko Sasaki, Yasukazu Hozumi, Kaoru Goto, Atsushi Natsume, Mika Watanabe et al. · 2013 · Biochemical and Biophysical Research Communications
99. Molecular pathology of bone tumours: diagnostic implications
    Florian Puls, Angela Niblett, D. Chas Mangham · 2013 · Histopathology
100. New Chondrosarcoma Cell Lines with Preserved Stem Cell Properties to Study the Genomic Drift During In Vitro/In Vivo Growth
     Verónica Rey, Sofía T. Menéndez, Óscar Estupiñán, Aida Rodríguez, Laura Mahiques Santos, Juan Tornín, Lucia Martínez-Cruzado, David Castillo, Gonzalo R. Ordóñez, Serafín Costilla et al. · 2019 · Journal of Clinical Medicine